Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04681105
Title Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors City of Hope Medical Center

hairy cell leukemia

systemic mastocytosis

B-cell acute lymphoblastic leukemia

hematologic cancer

T-cell acute lymphoblastic leukemia

Hodgkin's lymphoma

chronic myeloid leukemia

acute leukemia


Acetaminophen + Dexamethasone + Diphenhydramine + Flotetuzumab + Ranitidine

Dexamethasone + Diphenhydramine + Flotetuzumab + Ibuprofen + Ranitidine

Age Groups: senior | adult | child
Covered Countries USA

No variant requirements are available.